

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-46 (Cancelled)

47 (Currently amended). A method to treat a living body suffering from a disease selected from the group consisting of asthma, rejection reactions relating to grafting organs or tissues, graft-versus-host disease, rheumatoid arthritis, sepsis, autoimmune disease, and inflammatory diseases, comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises variants of the amino acid sequences of the constant regions of a non-human interleukin-18 antibody, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said ~~constant regions~~ variants being not equal to the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier.

48 (Currently amended). A method to treat a living body in need of immunosuppressive or anti-inflammatory treatment,

comprising administering an effective amount of a composition to the living body, wherein said composition comprises (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises variants of the amino acid sequences of the constant regions of a non-human interleukin-18 antibody, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said ~~constant regions~~ variants being not equal to the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier.

49 (Currently amended). A method to treat a living body suffering from a disease selected from the group consisting of asthma, rejection reactions relating to grafting organs or tissues, graft-versus-host disease, rheumatoid arthritis, sepsis, autoimmune disease, and inflammatory diseases, comprising administering an effective amount of a composition to the living body, said composition comprising (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises variants of the amino acid sequences of the constant regions of a non-human interleukin-18 antibody, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said ~~constant regions~~ variants being not equal to the

amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier, wherein the interleukin-18-neutralizing activity of said peptide per antigen-binding site is not lower than that of an immunoglobulin molecule comprising the amino acid sequences of SEQ ID NOs:1 and 2 as the light and heavy chain variable regions respectively.

50 (Currently amended). A method to treat a living body in need of immunosuppressive or anti-inflammatory treatment, comprising administering an effective amount of a composition to the living body, said composition comprising (i) an artificially produced peptide for neutralizing a biological activity of interleukin-18, which peptide comprises variants of the amino acid sequence of the constant regions of a non-human interleukin-18 antibody, and a part or the whole of the amino acid sequences of variable regions in a naturally occurring human or non-human interleukin-18 antibody, said ~~constant regions~~ variants being not equal to the amino acid sequences of the constant regions of said non-human interleukin-18 antibody, and (ii) a pharmaceutically acceptable carrier, wherein the interleukin-18-neutralizing activity of said peptide per antigen-binding site is not lower than that of an immunoglobulin molecule comprising the amino acid sequences of SEQ ID NOs:1 and 2 as the light and heavy chain variable regions respectively.

51 (Currently amended). The method of claim 47, wherein said artificially produced peptide is administered to said living ~~befy~~ body at a dose of 1 μ g to 1g per shot.

52 (Previously presented). The method of claim 48, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.

53 (Previously presented). The method of claim 49, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.

54 (Previously presented). The method of claim 50, wherein said artificially produced peptide is administered to said living body at a dose of 1 μ g to 1g per shot.